PepTalk 2017
PepTalk 2017
2014 Archived Content



Sunday, January 12 | 5:00-8:00 pm

Discovering and designing novel therapeutic monoclonal antibodies (mAb) is just the beginning. The expanding demand for high-quality antibodies with better specificities has resulted in significant improvements in traditional hybridoma and genetically modified cell line engineering and production methods. However, these newly formed hybridomas and cells often grow poorly or die, and their selection and cloning are laborious and time-consuming. This course is designed to explain recent advances in cell line engineering technologies and provide practical examples through case studies.

The topics to be covered:

  • Cell fusion/hybridoma techniques
  • High-throughput screening of cell libraries
  • Co-culture
  • Conditioning growth media


5:00 pm Welcome

Mary Ann Brown, Executive Director, Conferences, Cambridge Healthtech Institute

5:20 Synthetic Biology: Evolution and Revolution

Camille Delebecque, Ph.D., Founder and CEO, SynBio Consulting

Synthetic biology, one of the major new technologies of the 21st century, “raises the prospect of important benefits, such as the ability to accelerate vaccine development” (Barack Obama, Letter to Dr. Gutmann, 5/20/2010). In this introduction to the field, we will discuss it in the context of the history of science and see how it revolutionizes traditional molecular biology and genetic engineering. From evolution to revolution, this primer will help better comprehend the wealth of potential disruptive innovations synthetic biology will bring.

5:55 Dinner Break

6:30 Simultaneous Surface Display and Secretion of Proteins from Mammalian Cells Facilitate Efficient in vitro Selection and Maturation of Antibodies

Robert A. Horlick, Ph.D., Senior Director, Molecular Biology, AnaptysBio, Inc.

I will discuss how we identify fully human antibodies from our AnaptysBio Evolving Libraries (ABEL), which we then affinity mature using somatic hypermutation in mammalian cells to generate high-affinity lead candidates. We have established a method, based on alternative splicing, that simultaneously permits the secretion of a functionally active antibody and a surface-displayed version of the same antibody on the same cell. The method is versatile, permitting differing antibody formats to be displayed versus secreted.

7:05 Efficient Construction of Transgene-Amplified CHO Cell Lines by Cell Cycle Checkpoint Engineering

Takeshi Omasa, Ph.D., Professor, Institute of Technology and Science, University of Tokushima

We present a novel method to rapidly generate more high-producing cells by accelerating transgene amplification using cell cycle checkpoint engineering. The down- or up- regulation of a cell cycle checkpoint kinase or related kinases could contribute the effective construction method for gene-amplified CHO cell line.

7:40 Interactive Q&A with Instructors and Participants

8:00 Close of Short Course

Speaker Biographies:

Camille Delebecque, Ph.D., Founder and CEO, SynBio Consulting

Camille DelebecqueCamille is the Founder and CEO of SynBio Consulting. SynBio Consulting works with leading organizations across the private, public and social sectors – organizations eager to change and get an edge in Synthetic Biology and the ever-changing landscape of Life Sciences. From providing R&D expertise to assisting with science communication, strategic and business decisions, SynBio Consulting is passionate about taking on immense and world-changing challenges that matter to its clients. Prior to founding SynBio Consulting, Camille worked at Puretech Ventures on the Enlight Bioscience startup portfolio. He was a consultant for the Harvard Office of Technology Development, a Director of the Harvard Biotech Club and worked for the Life Science division of UNESCO. Camille is trained as a bioengineer and earned his Ph.D. in Synthetic Biology with the highest distinctions. His thesis work was published in leading scientific journals and made the cover of Science.

Robert Horlick, Ph.D., Senior Director, Molecular Biology, AnaptysBio, Inc.

Robert HorlickRobert Horlick is the Senior Director of Molecular Biology at AnaptysBio, where he is a co-founding scientist. AnaptysBio has been focused on the use of somatic hypermutation, or SHM, for antibody discovery and optimization since its inception in 2005. Prior to AnaptysBio, Dr. Horlick had been part of drug discovery research team efforts at DuPont, Pharmacopeia, Millennium and X-Ceptor Therapeutics. Dr. Horlick holds a B.S. in Microbiology from the University of Maryland, a Ph.D. in Biology from Johns Hopkins University, and was a Post Doctoral Associate in the Department of Biotechnology and Medical Products at DuPont. He has over 20 years of experience in the pharmaceutical industry.

Takeshi Omasa, Ph.D., Professor, Institute of Technology and Science, University of Tokushima

Takeshi OmasaDr. Omasa’s background is in biochemical engineering and cell and tissue engineering. Recently, his work has focused on the production of biologics in Chinese hamster ovary cells.

«Back to Short Courses